Study on HHV6 reactivation mechanism in DIHS focusing on virus-derived chemokine receptor

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461699
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Dermatology
• Research Institution: Nara Medical University
• Principal Investigator: ASADA HIDEO 奈良県立医科大学, 医学部, 教授 (60252681)
• Co-Investigator(Renkei-kenkyūsha): MORI YASUKO 神戸大学, 医学部, 教授 (50343257)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 薬剤性過敏症症候群 / DIHS / HHV-6 / ヒトヘルペスウイルス / 再活性化 / TARC / ケモカイン / CD134

Outline of Final Research Achievements

HHV-6 reactivation is involved in the pathogenesis of drug-induced hypersensitivity syndrome (DIHS), but the reactivation mechanism is still unclear. In this study, we aimed to elucidate the mechanism of HHV-6 reactivation focusing on the marked elevation of Th2-related chemokine (TARC) in the acute phase of DIHS and the fact that HHV-6 has TARC receptor.
As a result, we found that HHV-6 receptor (CD134) markedly increased on the T cell surface correlated with the elevation of serum TARC level in the acute phase of DIHS, and that blood HHV-6 DNA amount was also correlated with serum TARC level. These findings suggested that increased expression of CD134 associated with elevated TARC might be involved in HHV-6 reactivation in vivo.

Free Research Field

内科系臨床医学